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Aberrant genome-wide hypomethylation is thought to be
related to tumorigenesis by promoting genomic instability.
Since DNA methylation is considered an important mech-
anism for the silencing of retroelements, hypomethylation
in human tumors may lead to their reactivation. However,
the role of DNA hypomethylation in chronic myeloid
leukemia (CML) remains to be elucidated. In this study,
the methylation status of the LINE-1 (L1) retrotransposon
promoter was analysed in CML samples from the chronic-
phase (CP, n¼ 140) and the blast crisis (BC, n¼ 47). L1
hypomethylation was significantly more frequent in BC
(74.5%) than in CP (38%) (Po0.0001). Furthermore,
L1 hypomethylation led to activation of both ORF1 sense
transcription (Po0.0001) and c-MET gene antisense
transcription (Po0.0001), and was significantly asso-
ciated with high levels of BCR–ABL (P¼ 0.02) and
DNMT3b4 (P¼ 0.001) transcripts. Interestingly, in
CP-CML, extensive L1 hypomethylation was associated
with poorer prognosis in terms of cytogenetic response
to interferon (P¼ 0.004) or imatinib (P¼ 0.034) and
progression-free survival (P¼ 0.005). The above results
strongly suggest that activation of both sense and
antisense transcriptions by aberrant promoter hypomethy-
lation of the L1 elements plays a role in the progression
and clinical behavior of the CML.
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Introduction
The transition of chronic myeloid leukemia (CML) from
the chronic phase (CP) to the blast crisis (BC) is
characterized by the accumulation of molecular and
chromosomal abnormalities (Shet et al., 2002), but the
molecular mechanisms underlying this genetic instability
are poorly understood. A plausible model of disease
progression predicts that increased BCR–ABL expres-
sion promotes the secondary molecular and chro-
mosomal changes essential for the expansion of cell
clones with increasingly malignant characteristics,
and remains crucial for the malignant phenotype even
in advanced stages of the disease (Calabretta and
Perrotti, 2004). In fact, an opposite effect of BCR–
ABL levels on the expression of RAD51, DNA-PKcs,
and BRCA1 proteins has been reported, all of them
involved in promoting genomic instability associated
with defective repair of the DNA double-strand
breaks (Deutsch et al., 2001, 2003; Slupianek et al.
2001). However, a causal link between decreased repair
of DNA double-strand breaks and disease progression,
as well as between BCR–ABL expression and the
secondary genetic changes of BC-CML, has not been
yet demonstrated.
Genomic instability is a poorly understood phenotype
associated with tumor progression. Several reports
have shown that mammalian DNA methylation plays
an important role in maintaining genomic stability
unrelated to the effects of DNA methylation on gene
expression and that hypomethylation of DNA in tumor
cells is associated with genomic instability (Chen et al.,
1998; Rizwana and Hahn, 1999). Moreover, genomic
hypomethylation causes tumorigenesis in mice asso-
ciated with the acquisition of additional genomic
changes (Eden et al., 2003; Gaudet et al., 2003). A
link between hypomethylation and the stability of
whole chromosome arms is also found in the human
Immunodeficiency-Centromeric Instability-Facial Ano-
malies syndrome (Xu et al., 1999) and human tumors
(Lengauer et al., 1997; Wong et al., 2001; Schulz et al.,
2002; Eden et al., 2003).
Genome-wide changes in DNA methylation may, in
particular, affect those repetitive DNA sequences that
are comparatively rich in CpG dinucleotides andReceived 13 January 2005; revised 20 April 2005; accepted 20 May 2005
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contain a considerable fraction of total methylcytosine
in the genome (Prak and Kazazian, 2000). Retro-
transposons are the most important repetitive trans-
posable elements in the human genome. They are copied
into RNA, the RNA is reverse-transcribed into DNA,
and the DNA is inserted into the genome at a new
location (Deininger and Batzer, 2002). The human
genome is littered with remnants of the most prominent
non-long-terminal repeat (non-LTR) retrotransposon,
LINE-1 (L1) element, roughly half a million of which
are 50 truncated, inverted, or mutated to inactivity
(Ovchinnikov et al., 2002). It also contains roughly 5000
full-length 6 kb L1 elements, 60–100 of which are still
capable of retrotransposition (Brouha et al., 2003). The
full-length L1 elements contain a 50 untranslated region
(50 UTR) with an internal promoter (IP), a 1kb ORF1
that encodes a protein with RNA-binding capability, a
4 kb ORF2 that encodes a protein with endonuclease
and reverse transcriptase activities, a short 30 UTR, and
a poly(A) tail. The L1 promoter is unusual for two
reasons: (i) it contains a CpG island that is very heavily
methylated in normal individuals. Methylation includes
symmetric and asymmetric methylation at CpG dinu-
cleotides as well as methylation at non-CpG sites
(Woodcock et al., 1997). This DNA methylation limits
the ability of retroelements to be activated and
transcribed and to participate in recombination, and
also counteracts their tendency to endanger the stability
of the genome by amplification and recombination
(Yoder et al., 1997; Yu et al., 2001); (ii) L1s contain
within their 50 UTR not only a sense strand promoter
for their own transcription, but also an antisense
promoter (ASP). This ASP has been shown to provide
an alternative transcription start site for a number of
human genes including c-MET, a receptor tyrosine
kinase whose activation by hepatocyte growth factor
(HGF) can lead to transformation and tumorigenicity in
a variety of tumors (Speek, 2001; Higumann et al., 2002;
Birchmeier et al., 2003; Ma et al., 2003). Therefore, it is
believed that hypermethylation of L1 is a major defense
mechanism to repress these genetic elements that could
be otherwise very damaging if actively transcribed.
Hypomethylation-induced retrotransposition of L1
can inactivate tumor suppressor genes (such as APC in
colon cancer) (Miki et al., 1992) and the L1 promoter
inserted in the upstream of the oncogenes (as seen in
c-MYC in breast cancer) can activate them (Morse
et al., 1988). Furthermore, hypomethylation of L1 has
been reported in urothelial bladder carcinoma (Florl
et al., 1999), malignant testicular tumors (Bratthauer and
Fanning, 1992), hepatocellular carcinoma (Lin et al.,
2001), chronic lymphocytic leukemia (Dante et al., 1992),
and prostate carcinomas (Santourlidis et al., 1999). In
addition, in prostatic cancer, L1 hypomethylation was
associated with progressive tumors and chromosomal
abnormalities (Schulz et al., 2002).
Despite the important role of L1 hypomethylation in
promoting genomic instability and cancer progression,
its possible relevance in CML has not been evaluated.
In the present study, we show that L1 sense and
antisense transcriptions are activated by promoter
hypomethylation in CML and that this event is
frequently associated with the evolution of the disease
to the advanced phase.
Results
L1 is hypermethylated in normal bone marrow cells
We analysed L1 methylation in 50 normal bone marrow
samples. As expected, L1 promoter DNA sequences
were strongly methylated in normal bone marrow cells.
This is illustrated by the amplification of the methylated
sequences with the complete lack of nonmethylated
sequence amplification in the majority (36/50, 72%) of
these samples (Figure 1a). However, 28% of the non-
neoplastic marrow specimens displayed a slight amount
of L1 hypomethylation, as defined by the presence of
specific products in the melting curves from both
methylated (melting temperature 83.41C) and unmethy-
lated sequences (melting temperature 81.21C, Figure 1b
and c). Based on the background fluorescence intensity,
a cutoff level was determined for specific fluorescence
for both unmethylated and methylated sequences in
normal individuals. This threshold was used to calculate
the cycle threshold or crossing point (CP) of each
sample. The CP value was directly proportional to the
amount of target sequence present in the sample. The
normal sample, which showed the lowest difference in
CP between the target (methylated sequences) and the
reference (unmethylated sequence) sequences, was used
as control/calibrator sample for quantification of the L1
promoter methylation in both healthy individuals and
CML patients. It was considered as 100%.
Based on these prerequisites and to determine the
cutoff value for altered L1 promoter methylation in
CML samples, we quantified by means of qrt-methyla-
tion-specific PCR (MSP) the methylation status of the
L1 promoter in those healthy donors who showed some
degree of unmethylated sequence amplification. NL1
ratios fell between 100 and 231% (160745.0%). An NL1
ratio equal to or below 70.0% (determined as the mean
minor 2s.d.) was chosen to define hypomethylation of
L1 promoter in CML DNA samples.
L1 promoter is hypomethylated in CML samples
By qrt-MSP, CpG island of the L1 promoter was
revealed to be highly hypomethylated in Ph-positive
CML (K562, KU812, TCC-s, and KYO-1) cell lines
(median NL1 ratio: 3%, range: 1–3%), whereas Ph-
positive precursor-B (MY, TOM-1, BV173, and
NALM-20) cell lines showed normal levels of L1
methylation (median NL1 ratio: 85%, range: 85–90%,
Figure 2). Among CML patients, hypomethylation of
L1 promoter was more frequently observed in BC (35/
47, 74.5%) than in CP (53/140, 38%). This difference
was highly significant (Po0.0001). Furthermore, a more
profound level of hypomethylation was observed among
BC samples compared with CP samples (mean NL1
ratios: 37.5717.1% vs 46718%, P¼ 0.07).
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L1 hypomethylation in CML is associated with activation
of ORF1 sense transcription
Quantitative expression of ORF1 transcripts was assessed
by means of qrt-PCR using cDNA from a healthy donor
as control (it was considered as 100% of NORF1 ratio).
Normalized ratios for ORF1 were determined in bone
marrow specimens from 30 healthy individuals. NORF1
ratios fell between 37 and 100% (mean NORF1:
68.8712.2%). Among CML patients, those with methy-
lated L1 promoter showed a mean NORF1 (65720%)
similar to that found in healthy individuals; however,
mean NORF1 was significantly higher in those CML
patients who showed L1 promoter hypomethylation
(308.97128.1%, Po0.0001, Figure 3a). Moreover, an
NORF1 value equal to or above 130% (determined as the
mean NORF1 from normal individuals plus 5s.d.) was
chosen to define overexpression of ORF1 in CML RNA
samples. Using this cutoff value, overexpression of ORF1
was found in 88% of CML patients with L1 hypomethyl-
ated but only in 1% of CML patients with methylated L1
promoter (Po0.0001).
High levels of ORF1 expression were observed among
L1 hypomethylated Ph-positive CML (K562, KU812,
TCC-s, and KYO-1) cell lines (mean NORF1 ratio:
632%, range: 320–1120%), whereas L1 hypermethylated
Ph-positive precursor-B (MY, TOM-1, BV173, and
NALM-20) cell lines showed normal levels of ORF1
expression (mean NL1 ratio: 68%, range: 53–92%).
L1 hypomethylation in CML is associated with activation
of c-MET antisense transcription
L1 has two transcription-regulation regions located in
the 50 UTR: an internal or sense promoter driving
transcription of the full-length L1, and an ASP driving
transcription in the opposite direction into adjacent
Figure 1 Methylation status of L1 promoter in healthy individuals and CML patients. (a) MSP analysis of CpG island within L1
promoter in healthy individuals and CML patients. CP indicates chronic phase CML; BC indicates blast crisis CML; UM, unmethylated
sequences; M, methylated sequences. Promoter hypermethylation is observed in normal subjects (no amplification of unmethylated
sequences), whereas some degree of L1 hypomethylation was observed among CML patients (amplification of both methylated and
unmethylated sequences). (b) qrt-MSP melting curve analysis of a CML patient showing the presence of two specific PCR products:
unmethylated (dotted line, melting temperature 81.21C) and methylated L1 sequences (solid line, melting temperature 83.41C). (c) L1
promoter methylation level of a representative CML case (lines with triangles) and a control/healthy individual (lines with circles) as
measured by qrt-MSP. The difference between the crossing points of the methylated (fine lines) and unmethylated (bold lines) L1 sequences
was lower for the CML patient compared with that of the healthy individual, indicating a lower degree of methylation in the CML patient
(NL1 ratio for healthy individual: 100%;NL1 ratio for CML patient: 2%.NL1 ratios were calculated as described inMaterials and methods)
Figure 2 Methylation status of L1 promoter in Ph0-positive cell
lines. MSP analysis of CpG island within L1 promoter in six Ph0-
positive cell lines. UM, unmethylated sequences; M, methylated
sequences. Only K562 and KU812 cell lines showed L1 hypo-
methylation. A CML sample was used as positive control for
methylated and unmethylated reactions
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cellular sequences (Speek, 2001; Higumann et al., 2002).
Chimeric transcripts derived from the L1 ASP are highly
represented in expressed-sequence tag (EST) databases
(Speek, 2001; Higumann et al., 2002). One of these ESTs
(BF208095, 665 nt, six exons) contains spliced exons
identical to those found in the c-MET proto-oncogen
mRNA, suggesting that L1s containing active ASPs are
capable of interfering with normal c-MET gene expression
(Speek, 2001; Higumann et al., 2002). We performed a
search for alignments of the two sequences (full-length L1
and c-MET gene) using the BLAST2 finder program
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/b12.html). Re-
sults showed that the full-length L1 sequence was inserted
within intron 2 of the c-MET gene between 46 113 and
52 058nt. As shown in Figure 4, transcriptions by the L1
internal/sense promoter and c-MET promoter drive in
opposite directions. Therefore, c-MET gene has the same
direction of transcription as the L1 ASP. As transcription
of the adjacent genes by L1 ASP is orientation-dependent,
which means that only genes having the same transcrip-
tional orientation as the ASP can be transcribed and
processed, one could speculate that hypomethylation of
L1 promoter might influence c-MET expression.
Quantitative expression of c-MET transcripts was
assessed by means of qrt-PCR using cDNA from a
healthy donor as control (it was considered as 100% of
NMET ratio). Normalized ratios for c-MET were
determined in bone marrow specimens from 30 healthy
individuals. NMET ratios fell between 2 and 100% (mean
NORF1: 23.6720.2%). Among CML patients, those
with methylated L1 promoter showed a mean NMET
(20.6735.3%), similar to that found in healthy indivi-
duals; however, mean NMET was significantly higher in
those CML patients who showed L1 promoter hypo-
methylation (269.37250.6%, Po0.0001, Figure 3b).
Moreover, an NMET value equal to or above 125%
(determined as the mean NMET from normal individuals
plus 5 s.d.) was chosen to define overexpression of
c-MET in CML RNA samples. Using this cutoff value,
overexpression of c-MET was found in 61% of CML
patients with L1 hypomethylated, but in none of CML
patients with methylated L1 promoter (Po0.0001).
High levels of c-MET expression were observed in two
L1 hypomethylated Ph-positive CML cell lines (K562,
NMET ratio: 3267%, and KU812, NMET ratio: 2834%),
whereas Ph-positive CML TCC-s and KYO-1 cell lines
and L1 hypermethylated Ph-positive precursor-B (MY,
TOM-1, BV173 and NALM-20) cell lines showed
normal levels of c-MET expression (mean NL1 ratio:
29.8%, range: 1–42%).
In addition, surface expression of c-MET protein was
tested in marrow cells from 10 healthy donors. No
expression was found in CD34-positive cells, myeloid
CD33 cells or CD11b granulocytes. However, L1
hypomethylated CML patients who expressed high
levels of c-MET mRNA also displayed c-MET protein
expression on CD34 cells, myeloid CD33 cells and
granulocytes (Figure 5a). No expression was found on
blast cells from five BCR–ABL-negative acute leuke-
mias, whereas K562 cell line was positive for c-MET
surface expression (Figure 5b).
Figure 3 ORF1, c-MET, BCR–ABL, and DNMT3b4 expression in
CML patients as measured by qrt-PCR. Significantly higher levels
of ORF1 (a), c-MET (b), BCR–ABL (c), and DNMT3b4 (d)
transcripts were detected among L1 hypomethylated CML patients
compared with methylated patients
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The possibility that the high levels of c-MET
transcripts detected in CML were determined by
hypomethylation of its own promoter was ruled out by
means of MSP. Promoter of c-MET gene was invariably
unmethylated in all CML cases and healthy individuals,
suggesting that changes in the levels of c-MET mRNA
do not depend on the epigenetic regulation of its own
promoter (Figure 6a). Moreover, to determine the
relationship between L1 hypomethylation and ORF1/
c-MET expression, we treated the Ph0-positive ALL cell
lines TOM-1 and NALM-20 (both with L1 methylated
and nonexpressing ORF1 or c-MET) with the demethyl-
ating agent 50-aza-20-deoxycytidine (AZA). This treat-
ment induced L1 hypomethylation and expression of
both ORF1 and c-MET transcripts (Figure 6b).
L1 hypomethylation in CML is associated with
BCR–ABL and DNMT3b4 transcript levels
Several lines of evidence demonstrate that the mere
presence of the Ph-chromosome is not sufficient to
produce hypomethylation of the L1 promoter: (1) L1 is
Figure 4 Transcriptional regulation of the c-MET gene by the L1 ASP. Exons of the c-MET gene are represented by black rectangles.
Direction of transcription is indicated by arrows. Full-length L1 retrotransposon (white rectangle) is inserted in an inverted position
within intron 2 of the c-MET gene. Transcriptions by the L1 IP and c-MET gene drive in opposite direction. Note that c-MET gene has
the same direction of transcription as the L1 ASP
Figure 5 Expression of c-MET protein on normal and CML marrow cells. The expression of surface c-MET protein on normal and
CML marrow cells was measured by multiparametric flow cytometry using anti-c-MET MnAb. Histograms are shown after gating on
viable cells (IP low vs SSC) and specific cell subsets (CD34, CD33 or CD11b-PE vs SSC). Shaded-solid lines represent c-MET
expression and blank-dotted lines FITC-conjugated isotype control antibody. No expression was observed in healthy individuals,
whereas L1 hypomethylated CML patients showed c-MET expression in all the cell subsets studied (a). K562 cell line which expressed
c-MET protein was used as positive control (b)
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normally methylated in a group of CML patients; (2) L1
hypomethylation was not observed in Ph-positive ALL
cell lines, and (3) transfection of the L1 hypermethylated
MO7e cell line with p210BCR–ABL was not associated with
changes in the L1 methylation status (NL1 ratio of
MO7e: 91%; NL1 ratio of p210-MO7e: 89%, Figure 7).
However, L1 hypomethylation was associated with
high levels of BCR–ABL expression. Hypomethylated
patients showed higher BCR–ABL transcript levels
(mean NBCR–ABL ratio: 52744%) than patients with
methylated L1 (mean NBCR–ABL ratio: 28.3726.7%,
P¼ 0.02, Figure 3c). Furthermore, L1 hypomethylated
patients had higher levels of DNMT3b4 expression
(mean NDNMT3b4 ratio: 140071502.7%) than L1 methy-
lated patients (mean NDNMT3b4 ratio: 73.3739.6%,
P¼ 0.001, Figure 3d).
L1 hypomethylation, response to treatment, and clinical
outcome
The clinical and laboratory characteristics of CP-CML
patients with hypomethylated and normal L1 at
diagnosis are shown in Table 1. Individual factors such
as sex, age, spleen size, percentage of blast cells in the
peripheral blood, platelet count, hemoglobin level, and
WBC count were not significantly associated with L1
methylation status. When L1 methylation status was
correlated with pretreatment risk groups, no significant
association between L1 hypomethylation and high-risk
patients assessed by the Sokal, Hasford, and Kartanjian
scoring systems was found.
CML patients in this study were treated with
chemotherapy (mainly, hydroxyurea, n¼ 39), IFN-
based regimens (n¼ 76), or imatinib (n¼ 25). In all, 37
patients received stem cell transplantation (five auto-
logous, 32 allogeneic). The treatment modality and
number of patients who received transplantation were
similarly distributed between the two L1 methylation
groups (Table 1). Moreover, the mean times of IFN
administration were similar in methylated (30 months)
and hypomethylated (30.2 months) patients. Hypo-
methylation of L1 promoter was correlated with a poor
response to treatment (Table 1). Thus, the complete
hematologic response (CHR) rate was significantly
lower among hypomethylated patients than in patients
with methylated L1 promoter (78 vs 92%, P¼ 0.05).
Figure 6 Effect of L1 hypomethylation on sense/antisense
transcription. (a) MSP analysis of CpG island within c-MET gene
promoter in a healthy individual (C) and CML patients. Lack of
promoter methylation at c-MET gene is observed in all the cases.
Cþ indicates positive control for methylated reactions (human
genomic DNA universally methylated). (b) Effects of AZA
treatment on L1 sense/antisense transcription in the TOM-1 Ph0-
positive precursor-B ALL cell line (L1 hypermethylated and
lacking ORF 1/c-MET expression). Cells were treated with 2 or
4mM of AZA for 4 days. AZA treatment induced hypomethylation
of the L1 promoter and expression of ORF1 and c-MET transcripts
Figure 7 Effect of p210BCR–ABL transfection on L1 promoter
methylation. Transfection of the MO7e Ph0-negative myeloid cell
line (L1 hypermethylated) with p210BCR–ABL did not produce
changes in the methylation status of the L1 promoter. CML
patient was used as positive control for unmethylated and
methylated reactions
Table 1 Clinical characteristics at diagnosis and outcome of 140
chronic myeloid leukemia patients according to L1 methylation status
Feature L1 hypomethy-
lated (n¼ 53)
L1 methylated
(n¼ 87)
P
Sex (M/F), % 55/45 56/44 NS
Age, median (int. r) 48 (35–59) 49 (37–57) NS
Palpable spleen, % 62 56 NS
Median hemoglobin
(g/l) (int. r)
120 (97.7–129.3) 110 (83.5–119.1) NS
WBC 109/l, median
(int. r)
163 (61.2–348.1) 141 (53.1–228.5) NS
Median platelet count
109/l (int. r)
375 (281–652) 401 (264–612) NS
Median peripheral
blood blast as %WBC
(int. r)
1 (0–4.1) 1 (0–3.6) NS
Sokal score, %
High 34 25 NS
Low/Intermediate 66 75
Kantarjian score, %
Stage 3 48 42 NS
Stages 1–2 52 58
Hasford score, %
High 19 25 NS
Low/Intermediate 81 75
Treatment type, %
Chemotherapy 27 29 NS
Interferon 54 54
Imatinib 19 17
Transplantation 28 25
Response to treatment, %
CHR 78 92 0.05
MCR with IFN 3 32 0.004
MCR with imatinib 47 100 0.034
Disease progression 63 24 0.03
Death 45 31 0.08
(int. r) indicates interquartile range; CHR, complete hematologic
response; MCR, major cytogenetic response; IFN, interferon
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Among 76 patients under IFN therapy, a ‘major’
cytogenetic response was observed in 32% of patients
with methylated L1, but only in 3% of hypomethylated
patients (P¼ 0.004). A multivariate analysis including
the clinical factors described in Table 1 demonstrated
the methylation status of the L1 promoter to be the only
independent factor predicting the cytogenetic response
to IFN (Table 2). Among the 25 CP-CML patients
receiving imatinib as front-line therapy, the rate of
major cytogenetic response at 6 months was 100% in the
L1 methylated group, as compared with 47% in the L1
hypomethylated group (P¼ 0.034). In addition, the
molecular response rate (reduction of the NBCR–ABL
ratio greater than 2 log) was better for patients with
methylated L1 (80%) as compared with L1 hypomethy-
lated patients (18%, P¼ 0.036).
Survival data were available from all patients. During
the study period, hypomethylated patients had higher
progression (63 vs 43%, P¼ 0.03) and mortality rate (45
vs 31%, P¼ 0.08) than patients with methylated L1
(Table 1). Kaplan–Meier analysis revealed differences in
the length of the CP (Figure 8). The estimated median
PFS time for hypomethylated patients was 58.3 months
(95% confidence interval (CI), 33.1–83.5) compared to
96.8 months (95% CI, 82.5–111.1) for patients with
methylated L1 (P¼ 0.005). Multivariate analysis using a
forward stepping model showed that the methylation
status of the L1 promoter (P¼ 0.02) and the Hasford
risk group (P¼ 0.04) were the only independent factors
associated with PFS (Table 3).
Discussion
From three lines of evidence, the present study indicates
that L1 promoter hypomethylation is an important
feature in CML. Firstly, hypomethylation increased
from non-neoplastic marrow cells toward CML cells.
Secondly, an increase in L1 hypomethylation in the
CML patients with advanced disease was observed. To
our knowledge, the hypomethylation of L1 promoter is
the most common molecular abnormality associated
with BC-CML reported to date. Thirdly, high levels of
hypomethylation were an independent marker of poor
prognosis in a subset of patients with CP-CML.
Two mechanisms are possible to explain how L1
hypomethylation could influence CML:
(a) A legitimate model of disease progression in CML
predicts that increased BCR–ABL activity promotes the
accumulation of molecular and chromosomal altera-
tions directly or indirectly responsible for the malignant
phenotype of BC-CML cells (Calabretta and Perrotti,
2004). The significant association between high levels of
BCR–ABL expression and L1 hypomethylation ob-
served in our study suggests that L1 hypomethylation
could be one of such mechanisms employed by BCR–
ABL to generate an unstable genome in the malignant
cell. Deregulation of DNA methylation is thought to
contribute to genomic instability in cancer. Reactivation
of retroelements might represent a particularly impor-
tant consequence of DNA hypomethylation, since their
containment is a key function of DNA methylation in
mammalian genomes (Yoder et al., 1997). Retrotrans-
position of L1 sequences results in a highly unstable
branched DNA structure prone to undergoing recombi-
nation with accessible elements located nearby or even
elsewhere in the genome (Feng et al., 1996). Chromo-
some deletions and translocations probably caused by
retrotransposition events have indeed been observed in
several human cancers (Morse et al., 1988; Nagarajan
et al., 1990; Miki et al., 1992; Pomykala et al., 1994; Liu
et al., 1997). Moreover, a significant increase in the
expression of a variety of retrotransposons and direct
evidence for the hypomethylation of L1s has been
observed during human cellular transformation (Takai
et al., 2000; Menendez et al., 2004; Suter et al., 2004).
Figure 8 Kaplan–Meier survivor function for CML patients. PFS
curve for all the patients enrolled in this study according to the L1
methylation status
Table 2 Multivariate regression analysis for response to interferon
treatment in 76 CML patients
Variable Level of significance
P P*
L1 hypomethylation 0.001 —
Kantarjian score 0.9 0.1
Sokal score 0.9 0.2
Hasford score 0.1 0.2
*Significance after adjustment for L1 methylation status
Table 3 Multivariate Cox model for progression-free survival in 140
CML patients
Variable Level of significance
P P*
L1 hypomethylation 0.02 —
Kantarjian score 0.1 0.2
Sokal score 0.3 0.4
Hasford score 0.03 0.04
*Significance after adjustment for L1 methylation status
LINE-1 hypomethylation in CML
J Roman-Gomez et al
7
Oncogene
It is evident that L1 hypomethylation occurs in many
BC-CML patients, but whether this epigenetic change
is a cause or consequence of progression seems to be
unclear. Our data argue against the second alternative
because L1 hypomethylation was not only associated
with BC but also with a cohort of CP-CML patients.
Interestingly, these patients progress to BC much more
rapidly than CP patients lacking hypomethylation,
suggesting that hypomethylated patients ab initio may
be more prone to genomic instability, resembling those
patients with deletions of the derivative chromosome 9
(Huntly et al., 2003).
(b) The 50 UTR of L1 houses not only an IP but also
an ASP that drives transcription of adjacent cellular
genes (Speek, 2001; Higumann et al., 2002). L1
insertions are frequently found in AþT-rich DNA. As
coding sequences tend to be more GþC-rich, L1
elements, by preferring AþT-rich DNA, may be more
successful genomic parasites, because they can reach
higher copy numbers without causing too many
deleterious insertions. However, L1s can and do insert
into genes (Kazazian and Moran, 1998). We have found
that one of these genes is the c-MET proto-oncogen.
In fact, the c-MET gene has the same direction
of transcription as the L1 ASP, which is inserted in the
c-MET intron 2. Our paper demonstrates that epigenetic
changes in the L1 promoter alter the expression of the c-
MET gene. Hypomethylation of the L1 promoter was
associated with overexpression of c-MET mRNA and the
presence of c-MET protein in the CD34þ precursor cell
compartment of CML patients.
c-MET, which has been found to be overexpressed in
a variety of human tumors, is a unique receptor tyrosine
kinase with versatile role in regulating numerous
biological functions in response to HGF (Comoglio,
2001; Maulik et al., 2002; Birchmeier et al., 2003; Ma
et al., 2003). As c-MET is overexpressed in CML
patients with advanced disease or poor response to
conventional treatment, we can speculate that the
biological abnormalities in CML cells from these groups
of patients depend on the combined action of both
tyrosine kinases, BCR–ABL and c-MET. Interestingly,
whereas imatinib mesylate inhibits the BCR–ABL
tyrosine kinase, it has no inhibitory effect on c-MET
(Buchdunger et al., 2000). Therefore, these findings
provide a basis for using HGF/c-MET signaling
inhibitors as part of the therapeutic approach for
poor-risk CML patients (Christensen et al., 2003).
Although genome-wide hypomethylation is generally
observed in cancers, its mechanism remains unclear. As
maintenance of the fidelity of CpG dinucleotide
methylation through DNA replication requires a tightly
regulated DNMT expression in replicating cells, deregu-
lation of DNMTs might lead to hypomethylation. It is
well established that CML cells show phase-dependent
expression of DNMTs (Mizuno et al., 2001). In the CP,
levels of DNMTs are not significantly different from
those in normal cells. However, cells in the acute phase
show an increase in the levels of DNMT1, 3a, and 3b.
This suggests that upregulated DNMTs may contribute
to the pathogenesis of BC by inducing DNA hyper-
methylation. This hypothesis seems to be in disagree-
ment with our finding concerning frequent L1
hypomethylation in BC-CML. In order to clarify this
issue, we have studied the expression levels of
DNMT3b4, a splice variant of DNMT3b whose over-
expression correlates significantly with DNA hypo-
methylation in the pericentromeric satellite region
because it lacks the conserved methyltransferase motifs
IX and X and, therefore, it does not show DNMT
activity (Saito et al., 2002). Our results demonstrate that
overexpression of DNMT3b4 was significantly corre-
lated with the degree of L1 hypomethylation, suggesting
that DNMT3b4 may compete with other DNMT
variants for targeting to L1 promoter in CML patients.
In conclusion, our results strongly suggest that
activation of both sense and antisense transcriptions
by aberrant promoter hypomethylation of the L1
elements plays a role in the pathogenesis of the
evolution of CML to its advanced phase, as well as in
the clinical behavior of the disease in CP.
Materials and methods
Cell lines and samples
Four human Ph0-positive CML (K562, KU812, KYO-1, and
TCC-S) and four human Ph0-positive precursor-B ALL
(BV173, TOM-1, MY, and NALM-20) cell lines were obtained
from the American Type Culture Collection (Manassas, VA,
USA). The megacaryoblastic MO7e cell line and its human
p210BCR–ABL-overexpressing derivate were kindly provided by
Dr JE Dick (University of Toronto, Canada). The cells were
cultured in the appropriate medium until harvested for
extraction of DNA and RNA. Heparinized bone marrow cells
were collected from patients with CML, and from healthy
marrow donors. Immediately after harvest, total WBCs were
obtained by dextran sedimentation or by red cell lysis of
centrifuged buffy coat preparations. Mononuclear cells
(MNCs) were isolated from BC-CML and donors by
sedimentation on Ficoll-Hypaque gradients. More than 90%
of the MNC populations from acute-phase CML were
leukemic blasts. We studied 140 patients with Ph-positive
CP-CML, diagnosed between August 1982 and December
2003. The study was approved by the Investigational Review
Board in accordance with the policies of the Department of
Health and Human Services. All patients gave informed
consent for the use of their samples. The patients were
unselected for type of front-line therapy (39 patients received
chemotherapy alone, 76 interferon (IFN) plus citarabine, and
25 imatinib). A diagnostic sample in CP was available for
analysis in all patients. Paired samples, where both a
diagnostic sample and a BC sample were available, were
analysed in 47 patients (34 in myeloid BC and 13 in lymphoid
BC). BC was defined by the presence of at least 30% blasts in
the blood or bone marrow or extramedullary involvement.
Risk categories according to the Sokal, Kantarjian, and
Hasford score systems were determined as described pre-
viously (Sokal et al., 1984; Hasford et al., 1998; Kantarjian
et al., 1999). Hematologic and cytogenetic responses to IFN
and imatinib treatments were evaluated. CHR was defined by
a WBC count of less than 10 000mm3, a platelet count of less
than 450 000mm3, the presence of less than 5% myelocytes
plus metamyelocytes, the presence of less than 20% basophils
and the absence of blasts and promyelocytes in peripheral
blood, and the absence of extramedullary involvement.
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Cytogenetic response was assessed on the basis of G-
banding in at least 20 cells in metaphase per sample and was
defined as ‘major’, comprising complete responders (CR, 0%
Phþ metaphases) and partial responders (PR, 1–34% Phþ
metaphases), or ‘poor’, including patients with a minor (MinR,
35–94% Phþ metaphases), or no response (NR, 95–100%
Phþ metaphases).
Semiquantitative real-time methylation specific PCR
(qrt-MSP) of L1 promoter
Analysis of the L1 promoter (GeneBank: X58075, LINE-1
promoter consensus sequence) has revealed that L1 promoter
possesses a 372 bp CpG island located between 49 and 420 nt,
showing >60% CþG content and an observed-overexpected
CpG frequency of >0.6. Promoter methylation of L1 retro-
transposon was determined by the MSP method as reported
previously (Hermann et al., 1996). MSP distinguishes un-
methylated alleles of a given gene based on DNA sequence
alterations after bisulfite treatment of DNA, which converts
unmethylated but not methylated cytosines to uracils. Sub-
sequent PCR using primers specific to sequences correspond-
ing to either methylated or unmethylated DNA sequences was
then performed. Briefly, 1mg of genomic DNA was denatured
by treatment with NaOH and modified by sodium bisulfite.
DNA samples were purified using Wizard DNA purification
resin (Promega Corp., Madison, WI, USA), treated with
NaOH, precipitated with ethanol, and resuspended in 20 ml of
water. Qrt-MSP was performed in a rapid fluorescent thermal
cycler with three-colour fluorescence monitoring capability
(LightCycler, Roche), using 1 ml of bisulfite-modified DNA in
10ml reaction volume with 0.4mmol/l each primer, and 1ml of
10 LightCycler FastStar DNA Master SYBR Green I
(Roche Molecular Biochemicals). The final Mg2þ concentra-
tion in the reaction mixture was adjusted to 3.5mmol/l.
Amplification of the L1 methylated sequences was used as target
gene (forward, 50-GTCGAATAGGAATAGTTTCGG-30;
reverse, 50-ACTCCCTAACCCCTTACGCT-30). The follow-
ing program conditions were applied for qrt-MSP running:
denaturation program, consisting in one cycle at 951C for
10min; amplification program, consisting in 45 cycles at 951C
for 10 s, 651C for 10 s, and 721C for 10 s; melting program, one
cycle at 951C for 0 s, 401C for 60 s, and 901C for 0 s; and
cooling program, one cycle at 401C for 60 s. The temperature
transition rate was 201C/s, except in the melting program,
which was 0.41C/s between 40 and 901C. Amplification of the
L1 unmethylated sequences for each sample was performed as
reference gene (forward, 50-GTTGAATAGGAATAGTTTT
GGTTT-30; reverse, 50-ACTCCCTAACCCCTTACACTT-30).
It was amplified in the same run and following the same
procedure described above for methylated sequences. A
procedure based on the relative quantification of target
sequence (methylated sequences) vs their controls/calibrators
in relation to the reference sequence (unmethylated sequences)
was used to assess the degree of L1 promoter methylation.
Calculations were automatically performed by LightCycler
software (RealQuant, version 1.0, Roche). The normalized
ratio was obtained from the following equation and expressed
as percentage of the control/calibrator:
Normalized ratio ðNL1Þ ¼ðEtargetÞDCp targetðcontrolsampleÞ
 ðErefÞDCp refðcontrolsampleÞ
Efficiencies (E) of each gene were calculated from the slopes of
crossover points (Cp) vs DNA concentration plot, according
to the formula E¼ 10(1/slope). DCp corresponded to the
difference between control/calibrator Cp and sample Cp,
either for the target or for the reference sequences. The
selected control/calibrator was the bone marrow specimen
from a healthy donor. It was considered as 100% (this is not
an absolute value indicating a fully methylated patient, but a
relative value used as a measure for the relative level of L1
methylation in the particular sample). Water blanks were
included with each assay. Results were confirmed by repeating
bisulfite treatment and MSP assays for all samples. Occasion-
ally, equal amounts of PCR products were separated on a 2%
agarose gel, stained with ethidium bromide, and visualized
under UV light.
Expression of ORF1, c-MET, BCR–ABL, and DNA
methyltransferase 3b4 (DNMT3b4) transcripts
Expression of ORF1 (GeneBank: M19503 and M59450,
Human LINE-1 repeat mRNA with two open reading frames),
c-MET (GeneBank: X54559, Homo sapiens mRNA for MET
proto-oncogene), and DNMT3b4 (GeneBank: AF129268,
Homo sapiens DNMT3b4 mRNA) transcripts were analysed
by the RT–PCR technique. Total RNA was extracted from
marrow samples with Ultraspec (Biotecx, Houston, TX, USA)
following the manufacturer’s instructions. Reverse trans-
cription was performed on 1 mg total RNA, after heating
at 701C for 5min, with random hexamers as reaction primer.
The reaction was carried out at 421C for 45min in the presence
of 12U Avian Myeloblastosis virus reverse transcriptase
(Boehringer-Mannhein, Germany). Quantitative real-time PCR
(qrt-PCR) for ORF1, c-MET and DNMT3b4 expression was
performed with the LightCycler technology, using 1ml of
cDNA in 20 ml reaction volume with 0.4 mmol/l each primer
(ORF1-forward: 50-CCCCAATCTAGCAAGG-30; ORF1-
reverse: 50-AGAGATCCGCTGTTAGT-30; c-MET-forward:
50-GGTCAATTCAGCGAAGTCCT-30: c-MET-reverse: 50-CC
AGTGTGTAGCCATTTTGG-30; DNMT3b4-forward: 50-CG
GGATGAACAGTTAAAGAAAGTA-30; DNMT3b4-reverse:
50-CCAAAGATCCTTTCGAGCTC-30), and 2 ml of 10
LightCycler FastStar DNA Master SYBR Green I (Roche
Molecular Biochemicals). The final Mg2þ concentration in the
reaction mixture was adjusted to 3.5mmol/l. The following
program conditions were applied for qrt-PCR running:
denaturation program, consisting in one cycle at 951C for
8min; amplification program, consisting in 45 cycles at 951C
for 5 s, 601C for 10 s and 721C for 15 s; melting program, one
cycle at 951C for 0 s, 401C for 60 s and 901C for 0 s; and cooling
program, one cycle at 401C for 60 s. The temperature
transition rate was 201C/s, except in the melting program,
which was 0.41C/s between 40 and 901C. BCR–ABL expression
was detected as reported previously (Emig et al., 1999).
Abelson gene (ABL1) was employed as reference gene, and it
was amplified in the same run and following the same
procedure described above (forward: 50-CCCAACCTTTTC
GTTGCACTGT-30; reverse: 50-CGGCTCTCGGAGGAGAC
GTAGA-30). In order to reduce the variation between different
assays and samples, a procedure based on the relative
quantification of target genes vs their controls/calibrators in
relation to the reference gene was used. Calculations were
automatically performed by LightCycler software (RealQuant,
version 1.0, Roche). The normalized ratios (NORF1, NMET;
NBCR–ABL and NDNMT3b4), expressed as percentage of the
control/calibrator, were obtained by RealQuant software as
described above for qrt-MSP of L1 promoter. The selected
controls/calibrators were the Ph0-positive K562 cell line for
BCR–ABL transcripts and bone marrow specimens from
healthy donors for ORF1, c-MET, and DNMT3b4 transcripts.
They were considered as 100% expression.
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MSP and unmethylated-specific PCR assay of the c-MET
promoter and 50 UTR
In order to determine the methylation status of the CpG
dinucleotides located in the promoter and 50 UTR of the
c-MET gene, bisulfite-modified DNA was analysed by means
of MSP. A pair of primers, MF 50-GATATTCGTTTTTTAA
GCGTTAG-30 and MR 50-ACTCCCTAACCCCTTACGCT-30,
was designed for the methylated sequence of c-MET promoter
and UTR. A pair of primers, UF 50-TGGGTGGGGTAGA
GGTGG-30 and UR 50-ATCCATCCCCTAATCCACAAA-30,
was designed for the unmethylated sequence of the same
region also. Initial denaturation at 941C for 5min was
followed by 35 cycles of a denaturation step at 941C for
1min, an annealing step at 601C for 1min, and an extension
step at 721C for 1min, and a final extension step of 721C for
7min was added. The products were separated by electro-
phoresis on 2% agarose gel. Human male genomic DNA
universally methylated for all genes (Intergen Company,
Purchase, NY, USA) was used as a positive control for
methylated alleles. Water blanks were included with each
assay. PCR products were visualized on 2% agarose gels
stained with ethidium bromide. Results were confirmed by
repeating bisulfite treatment and MSP assays for all samples.
Detection of c-MET protein by flow-cytometric analysis
Total marrow cells (1–5 105) were incubated with unconju-
gated mouse anti-human c-MET monoclonal antibody
(MoAb) to detect the extracellular epitope of human MET
protein (Clone DO-24, Upstate Biotechnology, Lake Placid,
NY, USA). After two washes with phosphate-buffered saline
containing 0.2% bovine serum albumin and 0.2% sodium
azide (PBSA), cells were incubated with FITC-labelled goat
anti-mouse MoAb (Dako, Denmark). Isotype-matched con-
trol IgG2k was used to set up regions. PE-conjugated MoAbs
against human CD34, CD33, CD11b, CD19, and CD3
were used to identify stem cells, myeloid cells, granulocytes,
B-lymphocytes, and T-lymphocytes, respectively. Erythrocytes
were lysed after staining by adding 2.5ml of lysis solution
(0.155mol/l NH4Clþ 0.01mol/l KHCO3þ 104mol/l EDTA).
Finally, nonviable cells were excluded using propidium iodide
(Sigma, St Louis, MO, USA) at 1mg/ml. Three-color acquisi-
tion and analysis were performed using a dual laser
FACScaliburt flow cytometer with Cell Quest Software.
AZA treatment
ALL-derived TOM-1 and NALM-20 cell lines were grown at a
density of 750 000 cells/ml in 25 cm2 flasks with 8ml of RPMI
1640 medium supplemented with 20% fetal bovine serum and
maintained at 371C in a humid atmosphere containing 5%
CO2. Each of the cell lines was treated with 2 and 4 mM of AZA
(Sigma-Aldrich, Steinheim, Germany) for 4 days. After
treatment, cells were washed in PBS, pelleted by centrifugation
at 1500 r.p.m. during 5min and used for genomic DNA and
RNA isolation. DNA was extracted using QIAmp DNA Mini
Kit (Qiagen, Hilden, Germany) and total RNA using Rneasys
Mini Kit (Qiagen, Hilden, Germany). In all, 1mg of total RNA
was used for cDNA synthesis using SuperScriptt II RNase
H-RT (Invitrogen Life Technologies, Paisley, UK) with
random hexamers.
Statistical analysis
All calculations were performed with the SPSS statistical
package (SPSS, Chicago, IL, USA). Medians, s.d. and
interquartile ranges were calculated for age and clinical and
laboratory findings at diagnosis for patients with and without
L1 hypomethylation and tested for any significant differences
with the Mann–Whitney U-test (for continuous variables) or w2
analysis and Fisher exact test (for categorical variables).
Overall survival (OS) was calculated from time of diagnosis
to death from any cause and was censored only for patients
known to be alive at last contact. Progression-free survival
(PFS) was measured from CML diagnosis to the appearance of
BC or death without disease progression, and it was censored
only for those patients alive and without evidence of
progression at last follow-up. For both OS and PFS
calculations, bone marrow transplant recipients were censored
at the time of transplantation. Distributions of OS and PFS
curves were estimated by the method of Kaplan and Meier,
with 95% confidence intervals calculated by means of Green-
wood’s formula. Comparisons of OS and PFS between groups
were based on the log-rank test. Comparisons adjusted for
significant prognostic factors were based on Cox regression
models and hazard regression models. All progression and
survival data were updated on May 31, 2004, and all follow-up
data were censored at that point.
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